Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00658411 · ClinicalTrials.gov registry record · NA
Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation
A NA study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- NA
- Development phase
- 5
- Enrollment target
NCT00658411 is a NA study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 5 participants.
The verdict
NCT00658411, a NA study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
Study Summary
The objective of this research study is to determine the safety and feasibility of chelation therapy with deferoxamine for patients with iron overload who are receiving a stem cell transplant. Patients who have iron overload prior to stem cell transplantation may have more toxicity from the transplantation procedure, and thus may benefit from an attempt at iron chelation pre- and peri-transplantation. In this study we are examining the use of deferoxamine starting 2 weeks to 3 months prior to transplantation and continuing through the preparative regimen.
Interventions
- DRUG deferoxamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2008-08 |
| Est. Completion | 2011-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00658411
The ClinicalTrials.gov registry entry for NCT00658411 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which deferoxamine is the first listed.
NCT00658411 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00658411 about?
NCT00658411 is a clinical study titled "Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation". The objective of this research study is to determine the safety and feasibility of chelation therapy with deferoxamine for patients with iron overload who are receiving a stem cell transplant. Patients who have iron overload prior to stem cell transplantation may have more toxicity from the transpla...
What is the current status of trial NCT00658411?
This trial is currently terminated. It is a NA study. The enrollment target is 5 participants. The study started on 2008-08. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00658411?
The interventions under investigation include: deferoxamine (DRUG).
Who is sponsoring clinical trial NCT00658411?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.